Roche Warns Of Bigger Negative Impact From COVID-19 And Biosimilars

 
• By Jessica Merrill

Biosimilar competitors to Avastin, Herceptin and Rituxan and headwinds from COVID-19 are expected to have a CHF4.7bn negative impact in 2020, higher than the CHF4bn previously projected.

Dog in headwind at the stony beach
Roche faced headwinds from COVID-19 and biosimilars in H1 • Source: Shutterstock

More from Earnings

More from Business